Brief: Innate Pharma: AstraZeneca Will Discontinue INTERLINK-1 Phase 3 Study

Innate Pharma SA

01/08/2022 06:02

Aug 1 (Reuters) - Innate Pharma SA  IPH.PA :
    * INNATE PHARMA PROVIDES UPDATE ON ASTRAZENECA-SPONSORED
INTERLINK-1 PHASE 3 STUDY
    * FUTILITY INTERIM ANALYSIS OF INTERLINK-1 PHASE 3 STUDY
SPONSORED
BY ASTRAZENECA  DID NOT MEET A PRE-DEFINED THRESHOLD FOR
EFFICACY
    * ASTRAZENECA HAS INFORMED INNATE THAT STUDY WILL BE
DISCONTINUED
    * THERE WERE NO NEW SAFETY FINDINGS. ASTRAZENECA PLAN TO
SHARE
DATA IN DUE COURSE.

Source text for Eikon:  ID:nBwbGMFzHa 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))